Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that its two recently established rearing centers, located in the heart of one of Asia’s leading silk-producing regions, have now completely replaced the Company’s original Prodigy Textiles pilot facility as the center of production.
Since opening the first of these two new rearing centers in early 2024, Kraig Labs has produced more recombinant spider silk than in all previous years of the Company’s operations combined. These modern rearing centers provide an optimized production environment, combining advanced biotechnology with the region’s unmatched sericulture expertise, favorable climate, and established infrastructure.
Kraig Labs has already begun transferring equipment from its original pilot facility to the new commercial production centers, with the process expected to be completed by the end of August. The commercial production facilities will now be operated by the Company’s wholly owned subsidiary, Prodigy Silk. The Prodigy Textile brand will remain active as a DBA of Kraig Labs.
“This marks a major milestone for Kraig Labs,” said Jon Rice, COO of Kraig Labs. “By moving all of our resources into these purpose-built rearing centers, we are achieving a key expansion objective for 2025, operating in one of the world’s leading silk production locations. With the region’s natural advantages and our cutting-edge science, we are creating the strongest platform yet to deliver the promise of recombinant spider silk to global markets.”
The establishment of these rearing centers is the culmination of nearly a decade of planning. With operations now anchored in one of the world’s foremost silk-producing regions, Kraig Labs is taking a significant step forward in its mission to commercialize spider silk.
Get the latest news
delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit http://www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at http://www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
Advertisement
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to http://www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
Advertisement
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
Advertisement
(720) 288-8495
[email protected]
Advertisement
